Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 6/20 | 0.41 |
| ▸ | CA2 | P00918 | 6/20 | 0.41 |
| ▸ | CA12 | O43570 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16140623 | 0.93 | TDP1 (0.53) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL7527615 | 0.86 | EPHX1 (0.46) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL15341460 | 0.86 | EPHX1 (0.46) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL5498803 | 0.86 | TDP1 (0.42) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL3709339 | 0.85 | TDP1 (0.47) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL5490754 | 0.84 | HDAC4 (0.41) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL7519278 | 0.84 | PAOX (0.42) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL15332859 | 0.84 | TDP1 (0.41) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL5493643 | 0.84 | TDP1 (0.41) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL3486538 | 0.84 | CA1 (0.40) | TDP1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9669118-B2 | Method of labelling a biologically active molecule with 5-fluoro-5-deoxypentose or a 3-fluoro-3-deoxypentose | UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) | 2017-06-06 | — | — | US | disclosed |
| US-20140227181-A1 | METHOD OF LABELLING A BIOLOGICALLY ACTIVE MOLECULE WITH 5-FLUORO-5-DEOXYPENTOSE OR A 3-FLUORO-3-DEOXYPENTOSE | TURUN YLIOPISTO (FI) | 2014-08-14 | — | — | US | disclosed |
| US-20070191263-A1 | Valency platform molecules comprising aminooxy groups | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-08-16 | — | — | US | disclosed |
| US-20060141597-A1 | A conjugate of biologically active molecules e.g peptides, proteins, nucleic acids, hormones, lipids, antibodies, saccharides, epitopes, enzymes, drugs etc. and a polyoxyethylene containing aminoxy groups | JONES DAVID S | 2006-06-29 | — | — | US | disclosed |
| US-6858210-B1 | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same | LA JOLLA PHARMACEUTICAL CO. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20050004351-A1 | Therapeutic and diagnostic domain 1 beta2GP1 polypeptides and methods of using same | MARQUIS DAVID M (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040224366-A1 | Valency platform molecules comprising aminooxy groups | JONES DAVID S (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1183230-A1 | VALENCY PLATFORM MOLECULES COMPRISING AMINOOXY GROUPS | LA JOLLA PHARMACEUTICAL (US) | 2002-03-06 | — | — | EP | disclosed |
| EP-1092027-A1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 BETA 2 GP1 POLYPEPTIDES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (CA) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000075105-A1 | VALENCY PLATFORM MOLECULES COMPRISING AMINOOXY GROUPS | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999064595-A9 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME | JOLLA PHARMA (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999064595-A1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191263-A1 | Valency platform molecules comprising aminooxy groups | DAO, PAM, BCAT2 | TDP1 3756/4885CA1 553/4885CA2 1226/4885 |
| US-20060141597-A1 | A conjugate of biologically active molecules e.g peptides, proteins, nucleic acids, hormones, lipids, antibodies, saccharides, epitopes, enzymes, drugs etc. and a polyoxyethylene containing aminoxy groups | SHBG, DAO, DNPEP | TDP1 3051/4885CA1 111/4885CA2 370/4885 |
| US-20140227181-A1 | METHOD OF LABELLING A BIOLOGICALLY ACTIVE MOLECULE WITH 5-FLUORO-5-DEOXYPENTOSE OR A 3-FLUORO-3-DEOXYPENTOSE | FUT5, DUT, FUCA1 | TDP1 1609/4885CA1 1418/4885CA2 3098/4885 |
| US-20040224366-A1 | Valency platform molecules comprising aminooxy groups | DAO, PAM, BCAT2 | TDP1 3756/4885CA1 553/4885CA2 1226/4885 |
| US-20050004351-A1 | Therapeutic and diagnostic domain 1 beta2GP1 polypeptides and methods of using same | PLTP, PA2G4, PAG1 | TDP1 384/4885CA1 2816/4885CA2 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.